MCID: HYP064
MIFTS: 39

Hypogonadotropism

Categories: Endocrine diseases

Aliases & Classifications for Hypogonadotropism

MalaCards integrated aliases for Hypogonadotropism:

Name: Hypogonadotropism 12 55 15
Hypogonadism 73

Classifications:



External Ids:

Disease Ontology 12 DOID:7455
UMLS 73 C0020619

Summaries for Hypogonadotropism

MalaCards based summary : Hypogonadotropism, also known as hypogonadism, is related to hypogonadotropic hypogonadism 7 with or without anosmia and hypogonadotropic hypogonadism 23 without anosmia. An important gene associated with Hypogonadotropism is PRL (Prolactin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Hormone ligand-binding receptors. The drugs Menotropins and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include bone, pituitary and prostate, and related phenotypes are endocrine/exocrine gland and digestive/alimentary

Related Diseases for Hypogonadotropism

Diseases related to Hypogonadotropism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 hypogonadotropic hypogonadism 7 with or without anosmia 33.6 GNRH1 GNRHR RNF216
2 hypogonadotropic hypogonadism 23 without anosmia 33.4 GNRH1 GNRHR
3 hypogonadotropic hypogonadism 32.8 GNRH1 GNRHR KISS1 KISS1R
4 normosmic congenital hypogonadotropic hypogonadism 32.4 GNRH1 GNRHR KISS1 KISS1R
5 kallmann syndrome 32.4 GNRH1 GNRHR KISS1 KISS1R
6 hypogonadism 31.1 GNRH1 GNRHR KISS1 KISS1R
7 amenorrhea 30.4 GNRH1 PRL
8 hyperprolactinemia 29.9 GNRH1 PRL
9 precocious puberty 29.9 GNRH1 KISS1 KISS1R
10 hypopituitarism 29.9 GNRH1 PRL
11 hypothalamic disease 29.8 GNRH1 PRL
12 empty sella syndrome 29.8 GNRH1 PRL
13 anovulation 29.7 GNRH1 PRL
14 varicocele 29.7 GNRH1 PRL
15 craniopharyngioma 29.7 GNRH1 PRL
16 premature ovarian failure 1 29.5 GNRH1 PRL
17 polycystic ovary syndrome 29.5 GNRH1 PRL
18 central precocious puberty 29.4 GNRH1 KISS1 KISS1R
19 ovarian disease 29.4 GNRH1 PRL
20 hypogonadotropic hypogonadism 12 with or without anosmia 12.4
21 hypogonadotropic hypogonadism 1 with or without anosmia 12.4
22 hypogonadotropic hypogonadism 10 with or without anosmia 12.4
23 hypogonadotropic hypogonadism 21 with or without anosmia 12.4
24 hypogonadotropic hypogonadism 8 with or without anosmia 12.4
25 hypogonadotropic hypogonadism 11 with or without anosmia 12.4
26 hypogonadotropic hypogonadism 13 with or without anosmia 12.4
27 hypogonadotropic hypogonadism 15 with or without anosmia 12.4
28 hypogonadotropic hypogonadism 16 with or without anosmia 12.4
29 hypogonadotropic hypogonadism 20 with or without anosmia 12.4
30 hypogonadotropic hypogonadism 4 with or without anosmia 12.4
31 hypogonadotropic hypogonadism 9 with or without anosmia 12.4
32 hypogonadotropic hypogonadism 14 with or without anosmia 12.4
33 hypogonadotropic hypogonadism 17 with or without anosmia 12.4
34 hypogonadotropic hypogonadism 19 with or without anosmia 12.4
35 hypogonadotropic hypogonadism 22 with or without anosmia 12.4
36 hypogonadotropic hypogonadism 3 with or without anosmia 12.4
37 hypogonadotropic hypogonadism 5 with or without anosmia 12.4
38 hypogonadotropic hypogonadism 18 with or without anosmia 12.4
39 hypogonadotropic hypogonadism 6 with or without anosmia 12.4
40 hypogonadotropic hypogonadism 2 with or without anosmia 12.4
41 leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism 12.4
42 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 12.3
43 hypogonadotropic hypogonadism 24 without anosmia 12.3
44 adrenal hypoplasia, congenital 12.0
45 hypogonadotropic hypogonadism-severe microcephaly-sensorineural hearing loss-dysmorphism syndrome 11.9
46 multicore myopathy with mental retardation, short stature, and hypogonadotropic hypogonadism 11.9
47 hypogonadotropic hypogonadism without anosmia, x-linked 11.9
48 hypogonadotropic hypogonadism-frontoparietal alopecia syndrome 11.9
49 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 11.9
50 moebius syndrome-axonal neuropathy-hypogonadotropic hypogonadism syndrome 11.9

Graphical network of the top 20 diseases related to Hypogonadotropism:



Diseases related to Hypogonadotropism

Symptoms & Phenotypes for Hypogonadotropism

MGI Mouse Phenotypes related to Hypogonadotropism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.72 GNRH1 GNRHR KISS1 KISS1R PRL
2 digestive/alimentary MP:0005381 9.67 GNRH1 GNRHR KISS1 KISS1R
3 integument MP:0010771 9.65 GNRH1 GNRHR KISS1 KISS1R PRL
4 liver/biliary system MP:0005370 9.46 GNRH1 KISS1 KISS1R PRL
5 renal/urinary system MP:0005367 9.26 GNRH1 GNRHR KISS1 KISS1R
6 reproductive system MP:0005389 9.1 GNRH1 GNRHR KISS1 KISS1R PRL RNF216

Drugs & Therapeutics for Hypogonadotropism

Drugs for Hypogonadotropism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menotropins Approved Phase 4,Not Applicable 61489-71-2, 9002-68-0 5360545
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
3
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-18-4 6010
4
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 315-37-7 9416
5
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 5949-44-0
6
Anastrozole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 120511-73-1 2187
7
Dihydrotachysterol Approved Phase 4,Phase 2,Phase 1 67-96-9 5281010 5311071
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6
10
Dutasteride Approved, Investigational Phase 4,Phase 2,Phase 1 164656-23-9 6918296 152945
11
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 50-28-2 5757
12
Progesterone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 57-83-0 5994
13
Polyestradiol phosphate Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 28014-46-2
14 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 979-32-8
15
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
16
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
17 Nutmeg Approved Phase 4
18
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
19
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
20
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3 67-97-0 5280795 6221
21
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
22 Fertility Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Follicle Stimulating Hormone Phase 4,Phase 3,Phase 2,Not Applicable
24 Chorionic Gonadotropin Phase 4,Phase 3,Phase 2,Not Applicable
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
29 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
30 Vasodilator Agents Phase 4,Not Applicable,Early Phase 1
31 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Vardenafil Dihydrochloride Phase 4
34 Anabolic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
43 Central Nervous System Depressants Phase 4,Phase 2,Phase 1
44 Analgesics, Opioid Phase 4,Phase 2,Phase 1
45 Incretins Phase 4
46 Hypoglycemic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
47 insulin Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
48 Insulin, Globin Zinc Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
49 Micronutrients Phase 4,Phase 3,Phase 2,Not Applicable
50 Calciferol Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 360)
# Name Status NCT ID Phase Drugs
1 Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism Unknown status NCT02880280 Phase 4 Human Menopausal Gonadotropin;Human Chorionic Gonadotropin
2 Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Unknown status NCT02310074 Phase 4 Pulsatile Gonadotropin Releasing Hormone;Human chorionic gonadotropin;Urinary Follicle-Stimulating Hormone
3 Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism Unknown status NCT02140515 Phase 4 Lutropin alfa;Follitropin alfa and Lutropin alfa
4 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4 Testosterone
5 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
6 Effect of Androgel on Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
7 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
8 Testosterone for Peripheral Vascular Disease Unknown status NCT00504712 Phase 4 Testosterone;0.9% saline
9 Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ Completed NCT02937740 Phase 4 NATESTO Testosterone Nasal Gel
10 Effects of Medications in Patients With Hypogonadism Completed NCT01601327 Phase 4 Testosterone enanthate (Sustanon 250 mg);Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU);Testosteron gel (Testojel 50 mg)
11 Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism Completed NCT01107067 Phase 4 Sustanon
12 Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism. Completed NCT03619330 Phase 4 liraglutide;Testosterone
13 Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy Completed NCT02171390 Phase 4 Testosterone 250mg injection;Testosteron 50 mg transdermal gel
14 Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism Completed NCT01160341 Phase 4 Testosteron
15 Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment Completed NCT02111434 Phase 4 Testosterone
16 Sequential Therapy for Hypogonadotropic Hypogonadism Completed NCT01403532 Phase 4 Traditional intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH plus zinc
17 The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111473 Phase 4 Testosterone
18 The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism Completed NCT01533129 Phase 4 Testogel 50 mg transdermal gel;Testosterone 250mg injection
19 Vitamin D Treatment and Hypogonadism in Men Completed NCT01748370 Phase 4 Vitamin D supplementation in hypogonadal men;Vitamin D supplementation in eugonadal men;Placebo hypogonadal;Placebo eugonadal
20 Effects of Testosterone on Myocardial Repolarization Completed NCT03126656 Phase 4 Testosterone Undecanoate
21 The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
22 Testosterone Replacement in Men With Diabetes and Obesity Completed NCT01127659 Phase 4 testosterone;placebo
23 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
24 The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4 Testosterone Undecanoate,1000mg
25 TRADE-Testosterone Replacement and Dutasteride Effectiveness Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride
26 TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
27 Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
28 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel Completed NCT01893281 Phase 4 Topical Testosterone Solution
29 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4 dutasteride;placebo
30 Effect of Testosterone Replacement on Insulin Resistance Completed NCT00487734 Phase 4 Placebo for testosterone gel
31 Testosterone Replacement in Diabetes With Vascular Disease (Version 2) Completed NCT00355537 Phase 4 Testosterone;0.9% saline
32 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
33 Testosterone for Men With Insulin Treated Type 2 Diabetes Completed NCT00349362 Phase 4 Testosterone;0.9% saline
34 Testosterone Replacement in Metabolic Syndrome and Inflammation Completed NCT01123278 Phase 4 Testosterone;Placebo
35 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
36 Testosterone Replacement in Older Men and Atherosclerosis Progression Completed NCT00287586 Phase 4 Testosterone Gel (Androgel);Placebo
37 Subcutaneous vs. Intramuscular Testosterone Completed NCT03091348 Phase 4 Testosterone
38 Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) Completed NCT01560546 Phase 4 Testosterone;Placebo
39 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2) Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
40 Severe LH Suppressed Patients After Administration of a GnRH Antagonist Completed NCT01936077 Phase 4 Recombinant LH (Luveris)
41 FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women Completed NCT02674178 Phase 4
42 Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Completed NCT01201863 Phase 4 Androgel (Testosterone Gel);Androgel Placebo
43 The Health Influences of Puberty (HIP) Study Completed NCT01775813 Phase 4 Metformin
44 Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism Recruiting NCT03490513 Phase 4 anastrozole (1 mg/day);Placebo
45 Testosterone Therapy in Hypogonadal Men Treated With Opioids Recruiting NCT02433730 Phase 4 Testosterone;placebo
46 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters Recruiting NCT03203681 Phase 4 NATESTO® (4.5% nasal testosterone) Nasal Gel
47 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) Recruiting NCT03518034 Phase 4 Testosterone;Placebo
48 Periodontal Profile of Hypogonadic Men Recruiting NCT03176537 Phase 4 Testosterone gel;Placebos
49 Xiaflex® Plus Testosterone Treatment Pilot Study Protocol Recruiting NCT03815331 Phase 4 Xiaflex®;Aveed
50 TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY Recruiting NCT03325647 Phase 4 Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution;Placebo injectable saline

Search NIH Clinical Center for Hypogonadotropism

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Hypogonadotropism

Anatomical Context for Hypogonadotropism

MalaCards organs/tissues related to Hypogonadotropism:

41
Bone, Pituitary, Prostate, Skin, Testes, Brain, Liver

Publications for Hypogonadotropism

Articles related to Hypogonadotropism:

(show top 50) (show all 427)
# Title Authors Year
1
Similarities and differences in the reproductive phenotypes of women with congenital hypogonadotrophic hypogonadism caused by GNRHR mutations and women with polycystic ovary syndrome. ( 30476149 )
2019
2
Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene Therapy. ( 30046497 )
2018
3
Investigation of treatment for azoospermia due to male hypogonadotropic hypogonadism in Japan. ( 30302833 )
2018
4
Depression in Nonclassical Hypogonadism in Young Men. ( 30430144 )
2018
5
Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial. ( 30235049 )
2018
6
Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. ( 30389240 )
2018
7
Low Serum Testosterone in Outpatient Psychiatry Clinics: Addressing Challenges to the Screening and Treatment of Hypogonadism. ( 29128270 )
2018
8
Relationship between testosterone in serum, saliva and urine during treatment with intramuscular testosterone undecanoate in gender dysphoria and male hypogonadism. ( 29145707 )
2018
9
Clinical and biochemical correlates of male hypogonadism in type 2 diabetes. ( 29145714 )
2018
10
Examining the effect of the computer-based educational package on quality of life and severity of hypogonadism symptoms in males. ( 29157088 )
2018
11
Variation in Practice Pattern of Male Hypogonadism: A Comparative Analysis of Primary Care, Urology, Endocrinology, and HIV Specialists. ( 29183245 )
2018
12
High risk of hypogonadism in young male cancer survivors. ( 29245176 )
2018
13
Effects of aging, gender, and hypogonadism on mandibular bone density. ( 29292596 )
2018
14
Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: YES. ( 29424506 )
2018
15
Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: Not Yet. ( 29424507 )
2018
16
Homozygous nonsense mutation Trp28X in the LHB gene causes male hypogonadism. ( 29476300 )
2018
17
High prevalence of hypogonadism determined by serum free testosterone level in Japanese testicular cancer survivors. ( 29478250 )
2018
18
Pharmacological management of late-onset hypogonadism. ( 29505313 )
2018
19
Sleeve Gastrectomy Reversed Obesity-Induced Hypogonadism in a Rat Model by Regulating Inflammatory Responses in the Hypothalamus and Testis. ( 29508270 )
2018
20
Andrology: Ibuprofen and hypogonadism - bench to bedside to misinterpreted hype? ( 29508852 )
2018
21
Recovery from hypogonadism and male health in adult allogeneic stem cell transplantation. ( 29509972 )
2018
22
Anabolic steroid-induced hypogonadism: a challenge for clinicians. ( 29511645 )
2018
23
Evaluation and Treatment of Male Hypogonadism. ( 29550857 )
2018
24
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. ( 29562364 )
2018
25
Kratom, an Emerging Drug of Abuse, Raises Prolactin and Causes Secondary Hypogonadism: Case Report. ( 29568783 )
2018
26
S-Nitrosoglutathione Reductase (GSNOR) Deficiency Results in Secondary Hypogonadism. ( 29606625 )
2018
27
Absenteeism and Indirect Economic Burden Associated With Primary and Secondary Hypogonadism: A Retrospective Matched Cohort Analysis of Employed, Commercially Insured Patients in the U.S. ( 29634610 )
2018
28
MOSH Syndrome (Male Obesity Secondary Hypogonadism): Clinical Assessment and Possible Therapeutic Approaches. ( 29649106 )
2018
29
Sexual Dysfunction and Hypogonadism in Men With Diabetes. ( 29650102 )
2018
30
The complex association between metabolic syndrome and male hypogonadism. ( 29656047 )
2018
31
Association between cholesterol gallstones and testosterone replacement therapy in a patient with primary hypogonadism. ( 29656844 )
2018
32
Risk factors for late-onset hypogonadism. ( 29665142 )
2018
33
Correction for Kristensen et al., Ibuprofen alters human testicular physiology to produce a state of compensated hypogonadism. ( 29666267 )
2018
34
Seminal suPAR Levels as Marker of Abacterial Male Accessory Gland Inflammation in Hypogonadism. ( 29667546 )
2018
35
Possible mechanisms underlying fatty liver in a rat model of male hypogonadism: A protective role for testosterone. ( 29674209 )
2018
36
Re: Ibuprofen Alters Human Testicular Physiology To Produce a State of Compensated Hypogonadism. ( 29680733 )
2018
37
Hypogonadism and male obesity: Focus on unresolved questions. ( 29683196 )
2018
38
Normosmic idiopathic hypogonadotrophic hypogonadism due to a rare KISS1R gene mutation. ( 29692902 )
2018
39
Androgen Receptor CAG Repeat Length as a Risk Factor of Late-Onset Hypogonadism in a Korean Male Population. ( 29706560 )
2018
40
The risk of TESE-induced hypogonadism: a systematic review and meta-analysis. ( 29726895 )
2018
41
Hormone Replacement Therapy and Opioid Tapering for Opioid-Induced Hypogonadism Among Patients with Chronic Noncancer Pain: A Systematic Review. ( 29727002 )
2018
42
Editorial Comment to High prevalence of hypogonadism determined by serum free testosterone level in Japanese testicular cancer survivors. ( 29732674 )
2018
43
The efficacy and safety of short-acting testosterone ointment (Glowmin) for late-onset hypogonadism in accordance with testosterone circadian rhythm. ( 29734846 )
2018
44
Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study. ( 29772111 )
2018
45
Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies. ( 29774795 )
2018
46
Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study. ( 29777228 )
2018
47
Hypogonadotropic Hypogonadism in Men With Diabesity. ( 29934480 )
2018
48
Delayed puberty versus hypogonadism: a challenge for the pediatrician. ( 29969875 )
2018
49
Hiding in a plain sight: A high prevalence of androgen deficiency due to primary hypogonadism among acute medical inpatients with anaemia. ( 29992620 )
2018
50
Single-Centre Experience of Testosterone Therapy for Boys with Hypogonadism. ( 30021202 )
2018

Variations for Hypogonadotropism

Expression for Hypogonadotropism

Search GEO for disease gene expression data for Hypogonadotropism.

Pathways for Hypogonadotropism

GO Terms for Hypogonadotropism

Biological processes related to Hypogonadotropism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.46 GNRH1 GNRHR KISS1 KISS1R
2 response to organic cyclic compound GO:0014070 9.37 GNRH1 PRL
3 response to ethanol GO:0045471 9.32 GNRH1 PRL
4 female pregnancy GO:0007565 9.26 GNRH1 PRL
5 cellular response to hormone stimulus GO:0032870 8.96 GNRHR PRL
6 ovulation cycle GO:0042698 8.62 GNRH1 PRL

Molecular functions related to Hypogonadotropism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.62 GNRH1 PRL

Sources for Hypogonadotropism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....